Subcutaneous · GLP-1 / glucagon / FGF21 triple
DR10624
6 trials in this molecule. Source: ClinicalTrials.gov, as of July 6, 2026.
Trials
6
Ongoing
4
Recruiting
0
Completed
2
Sites
45
Countries
3
Endpoints
87
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 1
1
Phase 2
2
Phase 3
2
Not applicable
1
Trials by status
Not yet recruiting
2
By invitation
1
Active, not recruiting
1
Completed
2
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
30
Other (unclassified)
22
Glycemic / diabetes
11
MASH / liver
11
Weight & body composition
6
Cardiometabolic biomarkers
5
Other clinical outcomes
2
Top 20 metrics across this asset's endpoints
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
6 of 6
Showing 1-6 of 6 trials